185 related articles for article (PubMed ID: 35001868)
1. Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance.
Kimura H; Paranal RM; Nanda N; Wood LD; Eshleman JR; Hruban RH; Goggins MG; Klein AP; ; Roberts NJ
Elife; 2022 Jan; 11():. PubMed ID: 35001868
[TBL] [Abstract][Full Text] [Related]
2. The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer.
Kimura H; Klein AP; Hruban RH; Roberts NJ
Pancreas; 2021 Sep; 50(8):1123-1130. PubMed ID: 34714275
[TBL] [Abstract][Full Text] [Related]
3. Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in
Astiazaran-Symonds E; Graham C; Kim J; Tucker MA; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Sampson JN; Zhu B; Bruno W; Queirolo P; Fornarini G; Sciallero S; Carter B; Hicks B; Hutchinson A; Jones K; Stewart DR; Chanock SJ; Freedman ND; Landi MT; Höiom V; Puig S; Gruis N; Yang XR; Ghiorzo P; Goldstein AM
JCO Precis Oncol; 2022 Nov; 6():e2200145. PubMed ID: 36409970
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants.
Earl J; Galindo-Pumariño C; Encinas J; Barreto E; Castillo ME; Pachón V; Ferreiro R; Rodríguez-Garrote M; González-Martínez S; Ramon Y Cajal T; Diaz LR; Chirivella-Gonzalez I; Rodriguez M; de Castro EM; García-Seisdedos D; Muñoz G; Rosa JMR; Marquez M; Malats N; Carrato A
EBioMedicine; 2020 Mar; 53():102675. PubMed ID: 32113160
[TBL] [Abstract][Full Text] [Related]
5. Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.
Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG
JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008
[TBL] [Abstract][Full Text] [Related]
6. Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants.
Roberts NJ; Grant RC; Gallinger S; Klein AP;
Genes Chromosomes Cancer; 2021 Aug; 60(8):559-564. PubMed ID: 33724601
[TBL] [Abstract][Full Text] [Related]
7. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic
Overbeek KA; Rodríguez-Girondo MD; Wagner A; van der Stoep N; van den Akker PC; Oosterwijk JC; van Os TA; van der Kolk LE; Vasen HFA; Hes FJ; Cahen DL; Bruno MJ; Potjer TP
J Med Genet; 2021 Apr; 58(4):264-269. PubMed ID: 32482799
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic Cancer Surveillance in Carriers of a Germline
Klatte DCF; Boekestijn B; Wasser MNJM; Feshtali Shahbazi S; Ibrahim IS; Mieog JSD; Luelmo SAC; Morreau H; Potjer TP; Inderson A; Boonstra JJ; Dekker FW; Vasen HFA; van Hooft JE; Bonsing BA; van Leerdam ME
J Clin Oncol; 2022 Oct; 40(28):3267-3277. PubMed ID: 35658523
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer.
Astiazaran-Symonds E; Goldstein AM
J Gastroenterol; 2021 Aug; 56(8):713-721. PubMed ID: 34255164
[TBL] [Abstract][Full Text] [Related]
10. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk.
Campa D; Pastore M; Gentiluomo M; Talar-Wojnarowska R; Kupcinskas J; Malecka-Panas E; Neoptolemos JP; Niesen W; Vodicka P; Delle Fave G; Bueno-de-Mesquita HB; Gazouli M; Pacetti P; Di Leo M; Ito H; Klüter H; Soucek P; Corbo V; Yamao K; Hosono S; Kaaks R; Vashist Y; Gioffreda D; Strobel O; Shimizu Y; Dijk F; Andriulli A; Ivanauskas A; Bugert P; Tavano F; Vodickova L; Zambon CF; Lovecek M; Landi S; Key TJ; Boggi U; Pezzilli R; Jamroziak K; Mohelnikova-Duchonova B; Mambrini A; Bambi F; Busch O; Pazienza V; Valente R; Theodoropoulos GE; Hackert T; Capurso G; Cavestro GM; Pasquali C; Basso D; Sperti C; Matsuo K; Büchler M; Khaw KT; Izbicki J; Costello E; Katzke V; Michalski C; Stepien A; Rizzato C; Canzian F
Oncotarget; 2016 Aug; 7(35):57011-57020. PubMed ID: 27486979
[TBL] [Abstract][Full Text] [Related]
11. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.
Zhen DB; Rabe KG; Gallinger S; Syngal S; Schwartz AG; Goggins MG; Hruban RH; Cote ML; McWilliams RR; Roberts NJ; Cannon-Albright LA; Li D; Moyes K; Wenstrup RJ; Hartman AR; Seminara D; Klein AP; Petersen GM
Genet Med; 2015 Jul; 17(7):569-77. PubMed ID: 25356972
[TBL] [Abstract][Full Text] [Related]
12. High Growth Rate of Pancreatic Ductal Adenocarcinoma in
Ibrahim IS; Wasser MN; Wu Y; Inderson A; de Vos Tot Nederveen Cappel WH; Morreau H; Hes FJ; Veenendaal RA; Putter H; Feshtali S; van Mil AM; Gruis NA; Tollenaar RA; Bergman W; Bonsing BA; Vasen HFA
Cancer Prev Res (Phila); 2018 Sep; 11(9):551-556. PubMed ID: 29991580
[No Abstract] [Full Text] [Related]
13. Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.
Yang XR; Rotunno M; Xiao Y; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Bennett H; Graham C; Sampson JN; Malasky M; Vogt A; Zhu B; Bianchi-Scarra G; Bruno W; Queirolo P; Fornarini G; Hansson J; Tuominen R; Burdett L; Hicks B; Hutchinson A; Jones K; Yeager M; Chanock SJ; Landi MT; Höiom V; Olsson H; Gruis N; Ghiorzo P; Tucker MA; Goldstein AM
Hum Genet; 2016 Nov; 135(11):1241-1249. PubMed ID: 27449771
[TBL] [Abstract][Full Text] [Related]
14. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations.
Lal G; Liu L; Hogg D; Lassam NJ; Redston MS; Gallinger S
Genes Chromosomes Cancer; 2000 Apr; 27(4):358-61. PubMed ID: 10719365
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
[TBL] [Abstract][Full Text] [Related]
16. Risk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriers.
Ibrahim I; Sibinga Mulder BG; Bonsing B; Morreau H; Farina Sarasqueta A; Inderson A; Luelmo S; Feshtali S; Potjer TP; de Vos Tot Nederveen Cappel W; Wasser M; Vasen HFA
Eur J Hum Genet; 2018 Aug; 26(8):1227-1229. PubMed ID: 29769629
[TBL] [Abstract][Full Text] [Related]
17. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma.
Hu H; Zhu Y; Pu N; Burkhart RA; Burns W; Laheru D; Zheng L; He J; Goggins MG; Yu J
J Am Coll Surg; 2020 Nov; 231(5):527-535.e14. PubMed ID: 32659497
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
19. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer.
Terashima T; Morizane C; Ushiama M; Shiba S; Takahashi H; Ikeda M; Mizuno N; Tsuji K; Yasui K; Azemoto N; Satake H; Nomura S; Yachida S; Sugano K; Furuse J
Jpn J Clin Oncol; 2022 Oct; 52(10):1105-1114. PubMed ID: 36135357
[TBL] [Abstract][Full Text] [Related]
20. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.
Vasen H; Ibrahim I; Ponce CG; Slater EP; Matthäi E; Carrato A; Earl J; Robbers K; van Mil AM; Potjer T; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bergman W; Wasser M; Morreau H; Klöppel G; Schicker C; Steinkamp M; Figiel J; Esposito I; Mocci E; Vazquez-Sequeiros E; Sanjuanbenito A; Muñoz-Beltran M; Montans J; Langer P; Fendrich V; Bartsch DK
J Clin Oncol; 2016 Jun; 34(17):2010-9. PubMed ID: 27114589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
